RECORDATI UK LIMITED – Trademark Portfolio

Entity Type: 16

RECORDATI UK LIMITED holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include QARZIBA, SYLVANT, CAPHOSOL, and EUSA PHARMA. The owner is based in HEMEL HEMPSTEAD.

BREAKSPEAR PARK

BREAKSPEAR WAY

HEMEL HEMPSTEAD HP2 4TZ , GB

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

RECORDATI UK LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does RECORDATI UK LIMITED have?

RECORDATI UK LIMITED has 7 U.S. trademarks filed with the USPTO. Of these, 5 registered.

What trademark classes does RECORDATI UK LIMITED file in?

RECORDATI UK LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are RECORDATI UK LIMITED's most well-known trademarks?

RECORDATI UK LIMITED's registered trademark portfolio includes well-known marks such as QARZIBA, SYLVANT, CAPHOSOL, and EUSA PHARMA. These are among 5 currently registered trademarks in the portfolio.

What is RECORDATI UK LIMITED's trademark registration success rate?

RECORDATI UK LIMITED has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.